Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
CORE PRINCIPLE / WORLD VISION
CORE PRINCIPLE / WORLD VISION
VALUES
VALUES
History
History of Santen
Corporate Executives
Top Management
Corporate Executive
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
Santen 2030
Santen 2030
Medium-term Management Plan
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Quality Compliance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability at Santen
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Environment
Measures against Climate Change
Environmental Load Reduction
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Santen Initiatives
Santen Activities for Inclusive Society
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environmental Data 2022
Employment and Human Resources Data 2022
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2008
2008 News
Press Release
IR News
Information
Press Release
11.05.2008
Santen Announces Financial Result for the Second Quarter ended September 30, 2008
10.17.2008
Santen Announces Approval of TAPROS™ for Glaucoma and Ocular Hypertension Treatment in Japan
10.06.2008
Revision of Performance Forecast
10.03.2008
Santen to Launch Sante 40i OTC Eye Drop
08.04.2008
Santen Announces Financial Result for the First Quarter ended June 30, 2008
Press Release
IR News
11.05.2008
Santen Announces Financial Result for the Second Quarter ended September 30, 2008
10.17.2008
Santen Announces Approval of TAPROS™ for Glaucoma and Ocular Hypertension Treatment in Japan
10.06.2008
Revision of Performance Forecast
08.04.2008
Santen Announces Financial Result for the First Quarter ended June 30, 2008
07.02.2008
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
IR News
Information
Information
News Archive